Dopamine
Posted: Thu Mar 18, 2021 4:06 am
2021
Federal Center of Brain Research and Neurotechnology, Moscow, Russia
The prospect of dopaminergic therapy in multiple sclerosis
https://pubmed.ncbi.nlm.nih.gov/33728853/
Abstract
Dopamine is a direct mediator of neuroimmune interactions. Recent studies show that by acting on the dopaminergic receptors, it is possible to modulate Th17-immune response, which play a crucial role in the pathogenesis of multiple sclerosis. Dopamine can modulate Th17 cells function as well as dendritic cell-mediated Th17-immune response that allows considering dopaminergic receptors as a new therapeutic target in multiple sclerosis. In this short communication, the prospects of using dopaminergic therapy as a pathogenetic treatment for multiple sclerosis are discussed.
Federal Center of Brain Research and Neurotechnology, Moscow, Russia
The prospect of dopaminergic therapy in multiple sclerosis
https://pubmed.ncbi.nlm.nih.gov/33728853/
Abstract
Dopamine is a direct mediator of neuroimmune interactions. Recent studies show that by acting on the dopaminergic receptors, it is possible to modulate Th17-immune response, which play a crucial role in the pathogenesis of multiple sclerosis. Dopamine can modulate Th17 cells function as well as dendritic cell-mediated Th17-immune response that allows considering dopaminergic receptors as a new therapeutic target in multiple sclerosis. In this short communication, the prospects of using dopaminergic therapy as a pathogenetic treatment for multiple sclerosis are discussed.